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Why ultra high risk criteria for psychosis prediction do not work well outside clinical 
samples and what to do about it 
 
The use of ultra high risk (UHR) criteria in selected help-seeking samples is the only 
clinical possibility to alter the course of psychosis by preventing its onset. The UHR paradigm 
can additionally reduce the duration of untreated psychosis1 and provide extended benefits 
to patients who are experiencing a first episode of psychosis2.  
Because of these potentials, there is a great research potential and clinical interest in 
the use of UHR outside clinical samples, such as in the general population. The first 
epidemiological study investigating the significance of UHR criteria in the non-help-seeking 
general population aged 8-40 was published in this journal3. It indicated that only 1.3% of 
the general population met the Structured Interview for Psychosis-risk Syndromes (SIPS) 
UHR criteria3. The longitudinal fate of these individuals has just been released4. 143 UHR and 
131 controls were followed up for an average of 2.5 years, with three transitions to 
psychosis in the UHR group (psychosis risk = 2.09%) and no transition in the control group.  
These results are of great interest, as they may support the epidemiological validity of 
the UHR paradigm, although they are likely to be underpowered (assuming a 0.001% risk in 
the control group as continuity correction and an alpha = 0.05, the resulting power would be 
of 38% only). Beyond these limitations, the key finding of 2.09% psychosis risk (at 2.5 years) 
in people meeting UHR from the general population is of crucial clinical relevance. It is 
strikingly lower than the annualized 2-year 20% (95% CI: 17%-25%)5 transition risk in help-
seeking UHR samples, that are characterized by frequent comorbid affective disorders and 
functional impairments6.  
These findings clearly confirm that the prognostic accuracy of the UHR criteria strictly 
depends on the sample to which they are being applied. Indeed, clinical help-seeking 
samples of individuals undergoing UHR assessment are characterized by a substantial pre-
test risk enrichment (pre-test risk for psychosis)7 of up to 15% at 38 months8. As 
demonstrated in a previous paper in this journal9, the use of UHR assessment is associated 
with a small positive likelihood ratio of 1.82 and a modest ability to rule in psychosis9. 
Therefore, to reach some prognostic accuracy of clinical utility in individuals meeting UHR 
criteria, it is necessary to apply them to samples that are already enriched in psychosis risk, 
i.e., with a significant pre-test risk. For example, a recent study published in this journal10 has 
shown that meeting the UHR criteria given an underlying 22q11.2 deletion syndrome, a 
condition that is characterized by a substantial pre-test risk for psychosis, is associated with 
a 27.3% risk of psychosis at 32 months.  
These considerations clearly limit the practical utility of the UHR outside of clinical 
samples, as recently recognized by the recommendation no. 4 of the European Psychiatric 
Association, which suggests that the UHR assessment should be primarily offered to selected 
samples of subjects “already distressed by mental problems and seeking help for them”.  
At the same time, because of the potential benefits yielded by the UHR paradigm, it 
seems important to continue exploring the usefulness of an extended use of UHR 
assessment in several different samples. A first pragmatic approach to estimating the 
prognostic accuracy of the UHR assessment in several scenarios would be to use the meta-
analytical Fagan’s nomogram that we presented in a previous paper in this journal9. This 
nomogram is based on the intrinsic properties of the UHR assessment (such as the positive 
and negative likelihood ratios7) and can be applied to different populations with a given pre-
test risk of psychosis onset to estimate their post-test risk of psychosis at 38 months.  
Importantly, our nomogram has now been externally validated. In fact, with that 
nomogram, we had estimated a small post-test psychosis risk (less than 5% at 38 months) in 
the general population, a value that is similar to the real value observed in the 
epidemiological study discussed above4. Similarly, with our nomogram, we had estimated a 
post-test psychosis risk of 26% for patients affected with the 22q11.2 deletion syndrome9, 
which exactly matches to the real value recently reported in this journal10.  
The use of our nomogram can thus provide reliable estimates (along with 95% CIs) for 
post-test risk of psychosis in individuals meeting UHR criteria, given a determined pre-test 
risk. Using the nomogram, researchers can simulate the expected prognostic accuracy, and 
estimate the required sample size needed to test their hypotheses.  
Since the use of the UHR assessment outside clinical samples is likely to be associated 
with low predictive power, it is fundamental to perform accurate power calculations. In this 
scenario and considering the probability of infrequent events, a second approach could 
involve using sequential testing methods11, for example by using the SIPS in samples already 
enriched in psychosis-risk, as recently shown in this journal12. Sequential testing is 
traditionally adopted in medicine to enrich the risk of samples that are selected to undergo 
different diagnostic or prognostic tests.  
A third practical approach could be to better investigate the factors that modulate pre-
test risk enrichment in samples undergoing a UHR assessment. We have recently shown that 
it may be possible to stratify help-seeking individuals undergoing UHR assessment through 
the use of simple socio-demographic and clinical variables13. The predictive model has been 
externally validated and can be used to inform future research in the field, with the scope to 
improve prognostic accuracy of psychosis prediction. 
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